(Q46022676)

18 December 2017

title

Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. (English)

1 reference

18 December 2017

0 references

1 reference

1 reference

1 reference

3

1 reference

18 December 2017

author name string

Vincent H Gattone

series ordinal

1

1 reference

18 December 2017

Rachel M Sinders

series ordinal

2

1 reference

18 December 2017

Alexander G Robling

series ordinal

4

1 reference

18 December 2017

language of work or name

English

0 references

publication date

6 May 2009

1 reference

18 December 2017

published in

Kidney International

1 reference

18 December 2017

volume

76

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

178-182

1 reference

18 December 2017

Nephronophthisis-associated ciliopathies

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Sirolimus reduces polycystic liver volume in ADPKD patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.147

7 January 2021

Identifiers

DOI

10.1038/KI.2009.147

1 reference

18 December 2017

release_dahejoz4jjbhrjv5oc3cgujl5a

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dahejoz4jjbhrjv5oc3cgujl5a

24 November 2022

mapped directly with Wikidata item

1 reference

18 December 2017